Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-331719      Publish Date : Wednesday, October 23, 2013 Visit : 2923

Intl. Congress form | International Congress Report | International Congress Report For Faculty | 25th european congress of pathology

25th european congress of pathology
The Report of 25th european congress of pathology by Dr.maryam kadivar
Application Code :
306-0213-0035
 
Created Date : Monday, September 16, 2013Update Date : Sunday, October 13, 2013IP Address :194.225.48.226
Submit Date : Sunday, October 13, 2013Email : dmkadivar@gmail.com
Personal Information
Name : maryam
Surname : kadivar
School/Research center : pathology department
Possition : Associate professor
Tel : +98-21-66559462
E-mail : dmkadivar@gmail.com
Information of Congress
Title of the Congress : 25th european congress of pathology
Title of your Abstract : Ferroportin expression and its association with other prognostic factors in breast cancer
Venue : Lisbon
From : Saturday, August 31, 2013
To : Wednesday, September 04, 2013
Abstract(Please copy/paste the abstract send to the congress) : Objective: Breast cancer is the most common malignancy in women.
Recent studies described a marked decrease in the levels of ferroportin in breast cancer. More importantly, the presented results demonstrate convincingly the incredible diagnostic and prognostic value of ferroportin expression in breast cancer. This study was undertaken to define the presence of ferroportin in breast cancer and its association with breast cancer subtypes and tumor prognostic indicator.
Methods: The Ferroportin immunohistochemical evaluation was carried out using surgical specimens from 100 cases of breast carcinoma and scored semiquantitatively on a score of 0 to 2. The overall intensity of staining and its association with tumor subtype, and tumor characteristics, such as size, grade, lymph-node involvement, and classic prognostic factor including ER, PR, Her2/neu and Ki67 were investigated using Chi-square, analysis of variance.
Results: Twenty eight percent of cancer samples received staining intensity score of 1. No staining
Was seen in the remaining 72% of cases. Lower Ferroportin expression was significantly seen in cases with classic prognostic factor of poor outcome including, absence of estrogen receptor, lack of progesterone receptor, positive Her2/neu and basal like molecular subtype (P<0.05)
Conclusion: Measurement of Ferroportin expression might help aid prognosis and predict the clinical outcome of breast cancer.
Keywords of your Abstract : breast cancer, ferroportin,prognostic factor
Acceptance Letter :
The presentation : Poster
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? : none
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : more than 300 persons
Delegates from which countries presented in the congress? : almost from all country around the world
Were the delegates of any other organizations present in the congress? : No
If yes, please write the names of the organizations in the box :  
What were the responses to your talking points? Were specific questions or concerns raised? : just some ponit about different prognostic factor in breast cancer and the need for more investigation about different prognostic factors
If you met staff members, please list their full names & positions. : I met only one iranian pathologist from Mashahad( Dr Ghafarzadeh)
Please inform us if there are any follow up actions we need to talk with the members of the congress : Just to inform you and as I know and underestand no follow up action is needed or neccesary to talk with the members of the congress. In respect to previous congress which I had attended ,the number of Iranian pathologist were too low. So improving the political and financial situation may increase the number of attendant Iranian pathologist to be familiar with new aspect of pathology and molecular sciences.Co-operation with European and asian pathologist should be considered as future plan. Also we can invite them to come and give lecture in our annual congress.
Your experiences about the travel processes(Providing ticket, accommodation,...) : No special thing to mention
Please give a briefing of your own observations and outcomes of the congress: : This time there was not too much information about breast cancer except some more attention about evaluation of Ki67 in breast cancer which had strong controversy between different expertists. There was more emphasis on the way that breast cancer cell metastasis (molecular way). They showed some rare and beautiful cases in breast and GYN pathology.
Next congress which will be held in UK will emphasize on molecular pathology of the breast cancer. In respect to previous congresses which I had attended, the number of Iranian pathologist was too low. So improving the political and financial situation may increase the number of attendant Iranian pathologist in the congresses in order to be familiar with new aspect of pathology and molecular sciences. Co-operation with European, Middle East and Asian pathologist should be considered as future plan. Also we can invite them to come and give lecture in our annual congress.